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Research advisor Bradley Loren writes: “I have been lucky to have
had the opportunity to work with Cheyenne for the last two years.
She always strives to excel at everything she does, and I know
she will continue to do great things as a graduate student at the
University of Pennsylvania next year.”
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Bladder cancer is the fourth most common cancer in men and the
tenth most common in women, and while long-term survival is
more predominant compared to other common cancers, more than
47% percent of bladder cancer deaths could have been avoided
with an early diagnosis (Verma et al., http://dx.doi.org/10.1148/
rg.322115125). Initial diagnosis is generally made via cystoscopy,
but magnetic resonance imaging (MRI) can be considered superior
due to higher soft-tissue contrast that can detect small tumors
and increased accuracy in determining the extent of muscle
invasion. The Thompson Group has used ﬁbronectin attachment
protein (FAP) to target liposomes to bladder tumor cells.
To expound upon this previous work, we designed a synthetic
pathway for a peptide-targeted MRI contrast agent and have made
signiﬁcant progress toward the ﬁnal construct, which is composed
of HP-β-CD threaded onto a polymer core and further modiﬁed
with Gd-DOTA and a maleimide linker to attach the FAP peptide.
This type of construct is called a polyrotaxane (PR), and we have
shown that PRs whose CDs have been modiﬁed with Gd-DOTA
have a high relaxivity and extended contrast in various organs.
New preparation and attachment methods for the maleimide linker
are under investigation, as is the most effective coupling method
for the FAP peptide. Subsequent studies will include cell culture,
relaxivity measurements, and in vivo MR imaging with mice to
determine the agent’s targeting and contrast enhancement abilities.

A cartoon depiction of polyrotaxane formation. Hydroxypropylβ-cyclodextrin units are threaded onto the polymer core akin to
beads being threaded onto a string, followed by an endcapping
reaction to prevent dethreading. The polyrotaxane is further
modified with Gd-DOTA and the targeting FAP peptide to
produce the MR contrast agent.
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